Professor Walter Van Dyck contributes to business model for a European-wide health information ecosystem

Vlerick professor Walter Van Dyck has been appointed by the Innovative Medicines Initiative (IMI)  as a subject matter expert advising on the design and use of future health care business models enhancing biopharmaceutical R&D productivity and patient interaction in an era of personalised medicine.

The Innovative Medicines Initiative (IMI), a €2 billion euro budget joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients.

Professor Walter Van Dyck is honoured by this appointment.On a personal level this is a recognition of my expertise in the field of healthcare business model design encompassing collaboration between life sciences companies, hospitals, and health management organisations. From a broader perspective on EU level this project is a key step in the transformation from classical to individualised medicine enabled by digitising humans.

Walter will function as the business modelling expert in a team of medical and biopharmaceutical researchers and health IT experts. “The goals is to design a business model for a European-wide health information ecosystem allowing researchers to link on an immense scale patient health records, genomic data, survey data, imaging and biosensor data, and social, environmental and economic data. This will speed up the development of complex individualised medicines and mobile health applications initially in the fields of obesity and Alzheimer’s disease.

Related news

  1. Technology is set to transform the pharmaceutical industry

    Date: 11/04/2018
    Category: Research News
    Recently Professor Zeynep Erden joined our Healthcare Management Centre. She is an innovation and strategy scholar, with a special focus on technology and knowledge management in the pharmaceutical industry. “I try to understand what fosters or hinders innovation and which innovation strategies lead to competitive advantages for pharmaceutical companies. I’m particularly interested in how new technologies change the way organisations innovate.” She identifies three major trends that are currently shaping the innovation strategies of pharmaceutical companies: patients first, advanced data analytics and a call for better and cheaper medicines.
  2. Network formation in hospitals: how do they do it in Canada?

    Date: 22/11/2017
    Category: Research News
    Healthcare systems vary enormously across the world. Which is why every three years, our MINOZ Research Centre organises a study trip that gives members the opportunity to see how other countries do things. This year, participants from eight Belgian hospitals went to Canada to find out how the country organises hospital networks.
All articles